LEO Pharma unveils new scientific collaboration strategy

Wednesday, October 3, 2012 11:08 AM

LEO Pharma, a global pharmaceutical company specializing in dermatology and critical care, plans to establish five long-term, strategic research collaborations in Australia, France, Germany and the U.S. by the end of next year.

The ambitious initiative aims to supplement LEO Pharma’s internal R&D activities and deliver new treatment options to dermatology patients faster than ever before.

Each collaboration will integrate discovery research and exploratory clinical trials to an exceptionally high degree. The unique approach will enable LEO Pharma to explore many dermatological treatment solutions at once—reducing the time it takes to deliver new therapeutic options. 

The scope of the scientific collaboration strategy covers skin conditions in which LEO Pharma is already active, such as psoriasis, atopic dermatitis and actinic keratosis, as well as new therapeutic areas for LEO Pharma.

LEO Pharma has already formed its first collaboration—Charité, one of Europe’s oldest and largest university hospitals. The pair will establish a joint institute called I2DEAL, the International Institute of Dermatology and Allergy. Here, experts will conduct early exploratory clinical trials and explore the underlying mechanisms of disease in allergic and itchy skin conditions.

I2DEAL research will focus on itch and inflammation, which currently lack satisfactory treatment options, according to Maurer, director of research, dept. of dermatology and allerg, Charité. It is the first time that the Department of Dermatology and Allergy at Charité enters into collaboration with a private pharmaceutical company to such a high degree.

 “This marks the beginning of an exciting journey for LEO Pharma and the patients we serve,” said Kim Kjoeller, senior vice president, global development, LEO Pharma. “Not only will we identify and test treatment solutions that no one has explored before; we will also explore new therapeutic areas for LEO Pharma.”

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs